Does the ability of p53 heterozygosity to rescue a developmental phenotype necessarily imply a direct role for p53 in the phenotype, or does reducing p53 gene dosage improve embryonic growth and viability in general, perhaps explaining the growing number of genetic mutations associated with developmental retardation that respond to p53 dosage reduction? The gene discussed is TP53; the disease is Global developmental delay.